Safety and efficacy of HAIC or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e16288
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and efficacy of HAIC or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.

Feng Fang, Han Mu, Yunlong Cui, Yu Ge et al.
Journal of Clinical Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Safety and efficacy of HAIC or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.

Feng Fang, Han Mu, Yunlong Cui, Yu Ge, Chen Liu, Ping Chen, Lu Chen, Xiaomeng Liu, Dongming Liu, Qiang Wu, Xu Bao, Hongyuan Zhou, Tianqiang Song, Huikai Li, Wei Zhang
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Tianjin Medical University Cancer Institute and Hospital (CN)
Openalex Percentile: Top 82%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and efficacy of HAIC or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study. — Feng Fang, Han Mu, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS